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Abstract 
Purpose: To evaluate the leishmanicidal and cytotoxic activity of alcohol and non-alcohol extracts and 
saponins from Ilex laurina. 
Methods: Extracts were obtained by percolation with solvents of different polarities: hexane, 
dichloromethane, ethyl acetate and ethanol. The ethyl acetate extract was subjected to silica gel column 
chromatography eluting with a step gradient of dichloromethane-methanol. All products were evaluated 
in vitro for leishmanicidal activity against amastigotes of leishmania panamensis and cytotoxicity on U-
937 cells.  
Results: Two saponins were isolated from the ethyl acetate extract. The ethyl acetate extract showed 
high leishmanicidal activity against intracellular amastigotes of L. panamensis (EC50, 7.5 ± 1.5 µg/mL) 
and low activity against axenic amastigotes (EC50, 52.8 ±1.6 µg/mL); this extract showed also high 
cytotoxicity (LC50, 57.7 ± 12.1 µg/mL). Saponin 2 exhibited high activity against intracellular amastigotes 
(EC50, 5.9 ± 0.5 µg/mL) but also showed high cytotoxicity on U-937 cells (EC50, 25.7 ± 6.1 µg/mL). This 
compound showed similar leishmanicidal activity and cytotoxicity to meglumine antimoniate and 
amphotericin B, respectively, drugs currently used for the treatment of leishmaniasis.  
Conclusions: Based on these results, Ilex laurina is a potential source of compounds that can lead to 
the development of new therapeutic alternatives against leishmaniasis.  
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Protozoan  parasites  are  responsible  for  some  
of  the  most  common  and  devastating  
diseases affecting humans and other mammals  
[1]. Among these diseases is leishmaniasis, 
which causes the most deaths after malaria [2], 
the reason why it has become a priority for the 
World Health Organization (WHO) [2].  
 
Cutaneous leishmaniasis is endemic in the 
tropics and sub-tropics. It is often referred to as a 
group of diseases because of the broad 
spectrum of clinical manifestations, which range 
from small cutaneous nodules to gross mucosal 
tissue destruction. In America, cutaneous 
leishmaniasis can be caused by a multitude of 
Leishmania species, members of the Vianna 
subgenus, such as L. (V.) panamensis, L. (V.). 
braziliensis, and L. (V.). guayanensis, and 
members of the Leishmania subgenus, such as 
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L. (L.) amazonensis and L. (L.) mexicana [3]. 
Leishmaniasis caused by these Leishmania 
species are associated with recurrences or 
relapses and lesions are hard to heal in absence 
of treatment with specific drugs. 
 
Classical  antileishmanial  drugs,  pentavalent 
antimonials (meglumine antimoniate and sodium 
stibogluconate), pentamidine isothianate and 
miltefosine, show high toxicity, important side 
effects  and  are  largely  no  longer  effective  
because  of  the emergence of resistance in the 
parasites, thus becoming a major public health 
problem [4,5]. The lack of an effective 
leishmanicidal  drug  has  evoked  a  renewed  
interest  in medicinal  plants  as  sources  of  new  
chemotherapeutic compounds that are more 
effective and have fewer side effects [6-9]. 
 
In order to find new drugs to combat this disease, 
we have studied extracts of Ilex laurina, a native 
Colombian plant that is distributed in the country 
in the north of Central and Western mountain 
ranges, from 1600 to 2900 m [10]. The Ilex 
genus belongs to the Aquifoliaceae family, 
comprising nearly 400 species of global 
distribution [11]. In Colombia, Ilex genus involves 
35 species. I. paraguariensis or “yerba mate” is 
the most commercialized plant of South America 
because infusions of aerial parts show a variety 
of biological properties including antioxidant 
activity [12,13], cardiovascular effects [14,15], 
anti-parkinsonian effect [16], hypocholeste-
rolemic, hepatoprotective [12], stimulant of the 
central nervous system and diuretic [17]. 
Different Ilex species are used as tea for 
protection against heart and liver diseases, brain 
dysfunction, and maintenance of proper body 
weight [18]. Tea of Ilex guayusa (named 
“guyasa”) is used in southern Colombia 
(Amazon) and northern Ecuador as mild 
stimulant [19]. Antioxidant, antiproliferative and 
apoptotic activities of Ilex laurina infusion have 
also been reported [20].  
 
Based on the broad spectrum of biological 
activities that have been reported for Ilex species 
and the need for new therapies against 
leishmaniasis, this study aimed at evaluating the 
leishmanicidal and cytotoxic activity of extracts 






Leaves of I. laurina were collected during June 
2013 in the village of Santa Elena, municipality of 
Medellín (Antioquia, Colombia) and identified by 
Dr. Fernando Alzate (Biology Institute, University 
of Antioquia, Medellin, Colombia). A voucher 
specimen (no. Alzate-50622) was kept at 
University of Antioquia Herbarium.  
 
Extraction and isolation 
 
Powdered leaves (0.7 kg) of I. laurina were 
extracted successively with hexane, 
dichloromethane, ethyl acetate, and ethanol (10L 
each) in a percolator at room temperature and 
concentrated in vacuum to give the 
corresponding yields (66.6g [8.9 %], 124.3g [16.6 
%], 107.3g [14.3 %] and 128.4g [17.1 %], 
respectively). 
 
The ethyl acetate extract was subjected to silica 
gel column chromatography (5 × 80 cm) eluting 
with a step gradient of dichloromethane-
methanol (100:0, 90:10, 80:20, 70:30, 60:40, 
50:50, 40:60, 30:70, 20:80,10:90, 0:100, each 
500 mL), to obtain 10 fractions (F1 - F10) 
collected on the basis of their TLC profiles 
(dichloromethane-methanol-acetic acid 80:15:5). 
Fractions F4 and F8 were recognized as the 
most interesting ones, due to the appearance of 
black spots after spraying with universal reagent. 
Compounds 1 (30 mg, 5.8 %) was isolated from 
F8 and compound 2 (35 mg, 3.9 %) from F4, by 
preparative TLC using dichloromethane-




The extracts and compounds were subjected to 
in vitro cytotoxicity on mammalian cells and 
leishmanicidal activity on axenic and intracellular 
amastigotes of L. (V.) panamensis.  
 
In vitro cytotoxic activity in mammalian cells 
 
The cytotoxicity of the products was assessed 
based on the viability of the human promonocytic 
cell line U937 (ATCC CRL-1593.2TM) evaluated 
by the MTT (3 - (4, 5-dimethylthiazol-2-yl) - 2, 5-
diphenyltetrazolium bromide) method as 
described previously [21, 22]. Briefly, into each 
well of a 96-well cell-culture dishes were 
dispensed 100,000 cells/100 μL in RPMI-1640 
supplemented with 10 % FBS and 100 uL of the 
corresponding concentrations of the extracts and 
saponins. Six double serial diluted concen-
trations were evaluated starting at 200 µg/mL. 
The cells were incubated at 37ºC with 5 % CO2 
for 72 h in the presence of the extracts and 
saponins, and then the effect was determined by 
measuring the activity of the mitochondrial 
dehydrogenase by adding 10 µL/well of MTT 
solution (0.5 mg/mL) and incubating at 37 ºC for 
3 h. The reaction was stopped by adding a 50 % 
isopropanol solution with 10 % sodium dodecyl 
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sulfate for 30 min. Cell growth was determined 
based on the quantity of formazan produced, 
which was measured at 570 nm in a benchmark 
reader plate spectrophotometer (Bio-Rad 
Hercules, CA, USA). Cells cultured in the 
absence of products were used as cell growth 
controls, while cells cultured in presence of 
meglumine antimoniate and amphotericin B were 
used as cytotoxicity controls. Each concentration 
was tested in triplicate in two independent 
experiments. 
 
Cytotoxicity was determined in terms of cell 
viability and cell growth inhibition obtained for 
each compound, amphotericin B or medium 
alone. Percentages of viability were calculated 
using Eq 1.  
 
Viability (%) = (At/Ac)100 …………………. (1)  
 
where At is the absorbance of treated cells and 
Ac (i.e., absorbance of control cells) corresponds 
to 100 % viability.  
 
Cell growth inhibition was calculated as in Eq 2.  
 
Cell growth inhibition (%) = 100 – viability (%) …… (2)  
 
The results are expressed as 50 % lethal 
concentration (LC50), i.e., the concentration of 
drug that gives half-maximal inhibition of cell 
growth. LC50 was calculated by Probit method 
[23].  The cytotoxicity of each product was 
graded according to the LC50 value, based on 
this own scale: High cytotoxicity (LC50, < 50 
μg/mL); moderate cytotoxicity (LC50, > 50 to < 
200 μg/mL), and potential no cytotoxicity (LC50, 
>200 μg/mL). 
 
In vitro leishmanicidal activity on axenic and 
intracellular amastigotes 
 
Axenic and intracellular amastigotes of L. (V.) 
panamensis strain transfected with the green 
fluorescent protein 
(MHOM/CO/87/UA140epirGFP) were used for 
the in vitro testing of leishmanicidal activity of 
each extract and saponins. Parasites in their 
promastigotes form were cultured in modified 
diphasic NNN medium and phosphate buffer 
saline (PBS) was used as liquid phase and 
incubated at 26 ºC. In turn, axenic amastigotes 
were obtained from promastigotes cultured in 
Schneider's medium, pH 5.4 supplemented with 
20 % FBS and incubated at 32 ºC as described 
elsewhere [22].  Finally, intracellular amastigotes 
were obtained after infection of U937 cells with 
promastigotes; in brief, U937 cells were 
dispensed in 24-well plates at a concentration of 
300,000 cells/well and were treated with 1 µM of 
phorbol myristate acetate (PMA) for 48 h at 37 
ºC.  Then, cells were infected with promastigotes 
of in stationary growth phase (day 5) at a ratio of 
1:25 cell/parasite and incubated 3 h at 34 ºC in 5 
% CO2. Cells were washed twice with phosphate 
buffer solution (PBS) to eliminate not internalized 
parasites and fresh RPMI-1640 was added into 
each well (1 mL); plates were incubated again at 
34 ºC and 5 % CO2 to allow intracellular 
differentiation to amastigotes form.  After 24h of 
infection, cells were ready to be use in 
antileishmanial testing assay as described below. 
 
Activity against axenic amastigotes 
 
The ability of I. laurina to kill axenic amastigotes 
of L. (V.) panamensis was determined based on 
the viability of the parasites evaluated by the 
MTT method as described previously [21,22]. 
Axenic amastigotes obtained as described above 
were harvested, washed, and adjusted at 2 x 106 
parasites/mL in fresh Schneider's medium with 
20 % FBS. Into each well of a 96-well plate were 
dispensed  100 µL of parasite suspension ( 2 x 
105 axenic amastigotes) and then 100 µL of each 
concentration of the extracts and saponins were 
added. Four serial dilution (base four) were 
prepared starting at 100 µg/mL (100 - 25 - 6.25 - 
1.56 ug/mL). Plates were incubated at 32 ºC. 
After 72 h of incubation, the effect of products 
was determined by adding 10 µL/well of MTT 
and incubating at 32 ºC for 3 h. The reaction was 
stopped as described above and the quantity of 
formazan produced was measured in a 
benchmark reader plate spectrophotometer (Bio-
Rad Hercules, CA, USA) set at 570 nm. 
Parasites cultivated in the absence of the 
compounds and extracts but maintained under 
the same conditions were used as controls for 
growth and viability while parasites cultivated in 
the presence of meglumine antimoniate and 
amphotericin B were used as controls for 
leishmanicidal activity. Assays were performed at 
least twice with three replicates per each 
concentration tested. Antileishmanial activity was 
determined according reduction of parasite 
growth percentages obtained for each 
experimental condition. Parasite growth was 
calculated using Eq 3. 
 
Parasite growth (%) = (A1/A0)100 …………. (3) 
  
where A1 is the absorbance of treated axenic 
amastigotes) and A0. Is the absorbance of 
untreated axenic amastigotes, and corresponds 
to 100 % parasite growth. Thus parasite growth 
inhibition was calculated as in Equation 4.  
 
Parasite growth inhibition (%) = 100 - parasite growth (%) (4) 
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The results are expressed as 50 % effective 
concentration (EC50) which corresponds to the 
concentration of the drug that gives half-maximal 
reduction in parasite growth, calculated by Probit 
method [23]. The degree of leishmanicidal 
activity was established as convenience 
according to EC50 values, using a self-designed 
scale: EC50 < 20 μg/mL, moderate activity: EC50 
>20 to <50 μg/mL; and potential non activity: 
EC50 > 50 μg/mL. Selectivity index (SI), also 
known as therapeutic index (TI) was calculated 
by the ratio of cytotoxicity to leishmanicidal 
activity, as in Eq 5. 
 
SI = CL50/CE50 ……….………………………. (5) 
 
Activity against intracellular amastigotes 
 
The effects of I. laurina extracts and saponins 
against intracellular amastigotes of L. (V.) 
panamensis were evaluated by flow cytometry 
using the methodology described by Pulido et al 
[24] and by Varela et al [25]. After 24 h of 
infection of U937 cells, culture medium was 
replaced by fresh RPMI medium containing each 
product at the corresponding concentration (four 
serial dilution base four, were prepared starting 
at a concentration not exceeding the LC50 
previously determined). Infected and treated cells 
were maintained at 34 ºC and 5 % CO2 for 72 h. 
After 72 h cells were removed from the bottom 
plate with a trypsin/EDTA (250 mg) solution and 
pulled of cells were centrifuged at 1100 rpm 
during 10 minutes at 4 °C; the supernatant was 
discarded and cells were washed with 1 mL of 
cold PBS, centrifuged at 1100 rpm for 10 minutes 
at 4 °C, the supernatant was discarded and cells 
were suspended in 500 μL of cold PBS. Cells 
were analyzed in an argon laser flow cytometer 
(Cytomics FC 500MPL Beckman Coulter, Brea, 
CA, USA) reading at 488 nm of excitation and 
525 nm of emission and counting 20.000 events. 
Infected cells were determined according the 
positive events for green fluorescence 
(parasites). Infected cells treated  with 
amphotericin B and meglumine antimoniate were 
used as control for antileishmanial activity 
(positive control) while infected cells incubated in 
culture RPMI 1640 medium alone were used as 
control for infection (negative control). Each 
concentration of all products were tested in 
triplicate in two independent experiments 
[22,24,25]. Antileishmanial activity was 
determined based on the reduction in infected 
cells obtained for each experimental condition. 
Parasitemia (i.e., infection) was calculated 
according Eq 6.  
 
Infection (%) = infected and treated cells/infected 
and untreated cells)100 ………..…….. (6)  
Percentage inhibition was calculated using 
Equation 7.  
 
Inhibition (%) = 100 - % infection ………… (7)  
 
The results are also expressed as the EC50, 
defined and calculated as stated above [23]. In 
this case, EC50 corresponds to the concentration 
of drug that gives the half-maximal inhibition of 
intracellular parasites. The degree of 
leishmanicidal activity was also established 
according to EC50 values, using the same self-
designed scale described above. SI was also 




Identification of compounds isolated 
 
The compounds were identified as saponins 
(Figure 1), by NMR and MS analysis. These 
compounds have already been reported [26-28]. 
 
Compound 1: 1H NMR (300 MHz, pyridine-d5):  
δ 1.09 (3H, d, J = 6.1 Hz), 1.27 (3H, s, CH3), 1.29 
(3H, s, CH3),  1.43 (3H, s. CH3), 1.73 (3H, s,  
CH3), 1.77 (3H,  s,  CH3), 2.97 (lH,  s,  H-18), 
3.30 (lH,  dd, J  =  4,  11 Hz,  H-3), 5.21 (lH,  br  
s,  19-OH),  5.61  (lH,  br  t,  H-12),  6.29  (lH,  d,  
J =  6.8 Hz  anomeric  H). 13C NMR (75 MHz, 
pyridine-d5):  δ 38.4 (C1), 28.5 (C2), 77.2 (C3), 
48.6 (C4), 56.4 (C5), 23.7 (C6), 32.4 (C7), 40.1 
(C8), 46.8 (C9), 37.1 (C10), 24.0 (C11), 128.9 (C12), 
138.2 (C13), 42.0 (C14), 28.3 (C15), 26.1 (C16), 
47.2 (C17), 53.7 (C18), 72.6 (C19), 41.6 (C20), 26.2 
(C21), 37.0 (C22), 180.1 (C23), 23.7 (C24), 11.6 
(C25), 18.4 (C26), 25.5 (C27), 177.7 (C28), 26.5 
(C29), 15.8 (C30), 94.7 (G-1), 74.8 (G-2), 77.6 (G-
3), 70.1 (G-4), 78.0 (G-5), 61.6 (G-6). [M-H-] m/z 
663.4648. 
 
Compound 2:  1H NMR (300 MHz, pyridine-d5):  
δ 1.07 (3H, d, J = 6.1 Hz), 1.08 (3H, s, CH3), 1.09 
(3H, s, CH3), 1.27 (3H, s. CH3), 1.41 (3H, s,  
CH3), 1.69 (3H,  s,  CH3), 2.98 (lH,  s,  H-18), 
3.76 (2H, s, H23), 4.30 (lH,  dd, J  =  5.5,  11 Hz,  
H-3), 5.61  (lH,  sapparent,  H-12), 6.36  (lH,  d,  J =  
7.5 Hz  anomeric  H). 13C NMR (75 MHz, 
pyridine-d5):  δ 38.2 (C1), 26.0 (C2), 73.1 (C3), 
41.9 (C4), 48.2 (C5), 17.9 (C6), 32.3 (C7), 39.8 
(C8), 47.9 (C9), 36.5 (C10), 23.3 (C11), 128.1 (C12), 
138.2 (C13), 41.5 (C14), 28.3 (C15), 25.1 (C16), 
48.1 (C17), 53.6 (C18), 72.4 (C19), 41.3 (C20), 25.7 
(C21), 36.9 (C22), 66.3 (C23), 11.3 (C24), 16.3 
(C25), 15.2 (C26), 23.4 (C27), 177.2 (C28), 25.8 
(C29), 14.9 (C30), 94.3 (G-1), 72.2 (G-2), 77.1 (G-
3), 69.8 (G-4), 77.2 (G-5), 61.1 (G-6). [M+Na+] 
m/z 673.3937. 
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Figure 1: Chemical structure of ilexsaponin A, 1 and Rotungenoside, 2 
 
Table 1: In vitro leishmanicidal activity against axenic and intracellular amastigotes of L. (V.) panamensis and 
cytoxicity of extract and saponins from Ilex laurina 
 









Hexane 20.9 ± 4.3 > 100.0 > 100.0 <0.2 
Dichloromethane 17.0 ± 3.5 20.3 ± 3.2 12.3 ± 0.8 0.8/1.4 
Ethyl Acetate 57.7 ± 12.1 52.8 ±1.6 7.5 ± 1.5 1.1/7.7 
Ethanol > 200.0 > 100.0 > 100.0 < 2.0 
Ilexsaponin A, 1 > 200.0 > 100.0 > 100.0 < 2.0 
Rotungenoside, 2  25.7 ± 6.1 41.6 ± 1.5 5.9 ± 0.5 0.6/4.3 
Amphotericin B 
SbVd 
26.6 ± 5.5 
495.9 ± 55.6 
0.06 ± 0.01 
> 200.0 
0.04 ± 0.01 
6.3 ± 0.9 
443.3/532 
< 2.0/78.7 
Data represent the mean value +/- standard deviation. aLC50: Lethal Concentration 50; bEC50: Effective 
Concentration 50; c SI: selectivity index: LC50 / EC50; dSbV: pentavalent antimonial Meglumine antimoniate. 
Cytotoxic compound: LC50 <100 µg/mL. No cytotoxic compound: LC50 >200 µg/mL. Active compound: EC50 < 20 
µg/mL. Moderately Active: EC50 > 20 - < 50 µg/mL; Non Active: EC50>50 µg/mL 
 
Antileishmanial and cytotoxic activities 
 
The leishmanicidal activity and cytotoxicity of 
extracts and saponins as well as meglumine 
antimoniate and amphotericin B, were evaluated 
following the method previously reported in the 
literature [21-25]. The leishmanicidal activity and 
cytotoxicity expressed as EC50 and LC50 values 
of extracts and saponins respectively, are shown 
in Table 1. 
 
Based on the results shown in Table 1, the 
cytotoxicity of extracts varied among the solvent 
used. Thus, ethanolic extract was not cytotoxic 
for mammals U937 cells, exhibiting LC50 > 200 
µg/mL. The remaining extracts using ethyl 
acetate, hexane and dichloromethane were 
cytotoxic with LC50 < 100 µg/mL. Amphotericin B 
was cytotoxic (LC50 = 26.6 ± 5.5 µg/mL) and 
meglumine antimoniate was not cytoxic (LC50 = 
495.9 ± 55.6 µg/mL).  
 
Leishmanicidal activity was observed for ethyl 
acetate and dichloromethane extracts against 
intracellular amastigotes with EC50 values < 20 
µg/mL and moderately active against axenic 
amastigotes with values of EC50 > 20 µg/mL.  
The hexane (although cytotoxic for U937 cells) 
and ethanolic extracts were not active against 
intracellular or axenic amastigotes of L.(V.) 
panamensis with EC50 values > 100 µg/mL. 
Amphotericin B was highly active against both 
intracellular and axenic amastigotes of L. (V.) 
panamensis while meglumine antimoniate was 





The activity observed in axenic amastigotes and 
intracellular amastigotes of ethyl acetate extract 
(EC50 < 60 μg/mL), suggests that this extract 
could be considered as promising in the search 
of new compounds against leishmaniasis. Based 
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on this result, we performed a fractionation of the 
ethyl acetate extract and separated a major 
secondary metabolites which were identified as 
ilex saponin A, 1 and rotungenoside, 2 (Figure 1) 
by NMR and MS analysis  [26-28]. 
 
Saponin 2 showed similar leishmanicidal activity 
and cytotoxicity to meglumine antimoniate and 
amphotericin B, respectively, drugs currently 
used for the treatment of leishmaniasis. In 
addition, the compound exhibited a selectivity 
index ≥1 (SI = 4.3) leading to greater activity 
against the parasite than the toxicity against the 
host cell. Some studies have shown that these 
compounds are active against various types of 
leishmaniasis [29-32]. Saponin 1 was not active 
or cytotoxic against L. (V) panamensis or U937 
cells, respectively (Table 1). A possible 
explanation is the higher polarity due to 
carboxylic group, which could prevent the 
passage of the compound through the cell 
membrane.  
 
The dichloromethane extract was the one that 
presented the best activity against axenic 
amastigotes of L. (V.) panamensis. 
Unfortunately, the cytotoxicity shown by this 
extract makes it a non-promising candidate in the 
search for new leishmanicidal compounds due to 
the risk of toxicity and no selectivity thereof. 
However, additional studies on cytoxicity using 
other cell lines are needed in order discriminate 
whether the cytoxicity showed by this extract is 
against tumoral or non-tumoral cells. The hexane 
extract showed activity against human cells but 
no activity against the Leishmania parasite and 
ethanolic extract was not potentially cytotoxic for 
the human U-937 cells but also was not active 
against L. (V.) panamensis; therefore, these 
extracts are not considered in the search for new 




Based on both leishmanicidal and cytotoxic 
activities, only ethyl acetate extract has potential 
to provide lead compounds for the development 
of new drugs to treat leishmaniasis. Two 
compounds have been isolated and identified in 
this study, both of which are saponins. Saponin 2 
is a potential candidate for antileishmanial drug 
development based on its activity against 
Leishmania parasite. Although its cytotoxicity 
against U-937 cells is similar to amphotericin B, 
additional studies on cytotoxicity using other cell 
types are needed in order to determine whether 
the toxicity shown by this compound is against 
tumor or non-tumor cells. In addition, further 
studies are required to optimize the structure of 
the promising molecule and to validate if the in 
vitro activity against L. (V.)  panamensis 
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